Plasma Sphingomyelin as a Post-Treatment Monitoring Biomarker for Pathological Response in Locally Advanced Rectal Cancer
Cancers · 30.06.2026 · 18 (13) · 2124
DOI: 10.3390/cancers18132124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 30.06.2026. Verfasst von Pedro Brandão und 2 weiteren Autor:innen. Beteiligte Einrichtung: Colorectal Unit, Department of Surgery, Hospital de Santo António, Unidade Local de Saúde de Santo António (ULSSA), Largo Professor Abel Salazar, 409…. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Organ-preservation strategies in locally advanced rectal cancer (LARC) increasingly require accurate assessment of response to neoadjuvant therapy, yet magnetic resonance imaging poorly distinguishes complete from near-complete responses. We investigated plasma sphingolipid dynamics across multiple treatment timepoints as monitoring biomarkers for pathological response.
Methods
This single-centre cohort study included 86 patients with histologically confirmed LARC; 58 received neoadjuvant treatment followed by surgical resection with an evaluable Mandard tumour regression grade (TRG) and formed the response-evaluable cohort (19 good responders [TRG 1–2], 39 poor [TRG 3–5]). Plasma sphingomyelin (SM), sphingosine-1-phosphate and glucosylceramide were quantified by UPLC–MS/MS at baseline (M0), post-chemoradiotherapy (M1) and post-surgery (M2). Discrimination was assessed by receiver operating characteristic analysis and odds ratios, longitudinal trajectories by a linear mixed-effects model, and SM was compared head-to-head with serum carcinoembryonic antigen (CEA).
Results
SM did not discriminate response at baseline (M0 AUC = 0.53) but did after treatment (M1 AUC = 0.750, p = 0.024; M2 AUC = 0.786, p = 0.010; pooled AUC = 0.767; odds ratio 10.67 at a 164.0 mg/L cutoff; negative predictive value 84%). SM correlated inversely with TRG grade (Spearman ρ = −0.43, p = 0.016) and outperformed serum CEA (AUC 0.74 vs. 0.60). Trajectories diverged over time (mixed-model time × group interaction p = 0.023) with no baseline difference (p = 0.96): good responders increased SM by +22.5% from M0 to M2, whereas poor responders declined by −8.4%.
Conclusions
Plasma SM is not a pre-treatment predictor but emerges as a post-treatment monitoring biomarker for pathological response in LARC, supporting its integration into multimodal response assessment for organ-preservation decision-making. External validation in independent cohorts is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Colorectal Unit, Department of Surgery, Hospital de Santo António, Unidade Local de Saúde de Santo António (ULSSA), Largo Professor Abel Salazar, 4099-001 Porto, Portugal.
- School of Medicine and Biomedical Sciences (ICBAS), University of Porto, 4050-313 Porto, Portugal.
- Unit for Multidisciplinary Research in Biomedicine (UMIB), School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.
- ITR-Laboratory for Integrative and Translational Research in Population Health, Rua das Taipas 135, 4050-600 Porto, Portugal.
- Laboratório de Bioquímica Genética, Serviço de Genética Laboratorial, Centro de Genética Médica Doutor Jacinto Magalhães, Clínica de Genética e de Patologia, Unidade Local de Saúde de Santo António (ULSSA), 4099-001 Por…
ORCID-Profile: Pedro Brandão
Zitieren
APA
Brandão, P., Lacerda, L., & Santos, M. D. (2026). Plasma Sphingomyelin as a Post-Treatment Monitoring Biomarker for Pathological Response in Locally Advanced Rectal Cancer. Cancers, 18(13), 2124. https://doi.org/10.3390/cancers18132124
Vancouver
Brandão P, Lacerda L, Santos MD. Plasma Sphingomyelin as a Post-Treatment Monitoring Biomarker for Pathological Response in Locally Advanced Rectal Cancer. Cancers. 2026;18(13):2124. doi:10.3390/cancers18132124
BibTeX
@article{Brando2026,
author = {Brandão, Pedro and Lacerda, Lúcia and Santos, Marisa D},
title = {Plasma Sphingomyelin as a Post-Treatment Monitoring Biomarker for Pathological Response in Locally Advanced Rectal Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {13},
pages = {2124},
doi = {10.3390/cancers18132124}
}
EUVIMED